http://orcid.org/0000-0003-2603-7488
References
- Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 1994;271(9):703–707.
- Abbott DS, Hezelgrave NL, Seed PT, et al. Quantitative fetal fibronectin to predict preterm birth in asymptomatic women at high risk. Obstet Gynecol. 2015;125(5):1168–1176.
- Roelens K, Roberfroid D, Ahmadzai N, et al. Prevention of preterm birth in women at risk: selected topics. Good Clinical Practice (GCP). Bruxelles: Centre Fédéral d’Expertise des Soins de Santé (KCE); 2014:1–40; KCE Reports 228Bs.D/2014/10.273/xx. Available from: http://kce.fgov.be/sites/default/files/page_documents/KCE_228_Preterm%20birth_Report.pdf.
- Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med. 1991;325(10):669–674.
- Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–2116.
- Wing DA, Haeri S, Silber AC, et al. Placental alpha Microglobulin-1 compared with fetal fibronectin to predict preterm delivery in symptomatic women. Obstet Gynecol. 2017;130(6):1183–1191.
- Melchor JC, Navas H, Marcos M, et al. Predictive performance of PAMG-1 vs fFN test for risk of spontaneous preterm birth in symptomatic women attending an emergency obstetric unit: retrospective cohort study. Ultrasound Obstet Gynecol. 2018;51(5):644–649.
- Riboni F, Vitulo A, Dell’Avanzo M, et al. Biochemical markers predicting pre-term delivery in symptomatic patients: phosphorylated insulin-like growth factor binding protein-1 and fetal fibronectin. Arch Gynecol Obstet. 2011;284(6):1325–1329.